Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study
European Journal of Clinical Investigation · 2026
DOI: 10.1111/eci.70268 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Raffaele De Caterina und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pisa and Pisa University Hospital, Pisa, Italy. Hauptthemen laut MEDLINE: Thiazoles, Pyridines, Stroke, Renal Insufficiency, Chronic. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Europe.
Abstract (Originalsprache)
Background
Non‐vitamin K oral anticoagulants, like edoxaban, are essential in managing atrial fibrillation (AF). The impact of renal function on edoxaban dosages in real‐world settings remains unclear. This 4‐year ETNA‐AF‐Europe study follow‐up analysis investigated how chronic kidney disease (CKD) stages affect the safety and effectiveness of usual edoxaban doses.
Methods
ETNA‐AF‐Europe (NCT02944019) was an observational study conducted from 2016 to 2022 across 776 centres in 10 European countries. Hazard ratios (HR) and annualized event rates were calculated for all‐cause death, cardiovascular (CV) death, stroke and bleeding events for the overall population and participants stratified by dose (30/60 mg) and CKD stages at baseline.
Results
Of the 13,164 participants in the full analysis set, 9114 participants with CKD (Stage 1, n = 2064; Stage 2, n = 4855; Stage 3, n = 1985; Stage 4, n = 135; missing, n = 75) received label‐recommended edoxaban doses. Compared with CKD Stage 1, higher CKD stages were associated with increased risks for stroke (Stage 3: HR [95% CI]: 1.889 [1.240–2.878], p = 0.003) and CV death (HR [95% CI]; Stage 4: 14.450 [8.270–25.247], Stage 3: 4.672 [3.312–6.969], Stage 2: 2.066 [1.394–3.062], all p < 0.001). All‐cause death followed a similar trend. After adjusting for age, sex, body weight, CHA 2 DS 2 ‐VASc and modified HAS‐BLED scores, most bleeding and effectiveness outcomes showed no nominally significant differences across CKD stages.
Conclusions
Edoxaban in patients with AF is effective and well tolerated across CKD stages and appropriate label dosing can offset the risk from renal impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pisa and Pisa University Hospital, Pisa, Italy.
- Daiichi Sankyo Europe GmbH, Munich, Germany.
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
- Institute of Molecular Biology and Genetics, Ariano Irpino, Italy.
- Association for Hypertension, Nephrology, and Kidney Transplant (IPNET), Nephrology, Great Metropolitan Hospital, Reggio Calabria, Italy.
ORCID-Profile: Raffaele De Caterina, Joana Nunes, Carmine Zoccali
Förderung
- Daiichi Sankyo Europe GmbH
- Daiichi Sankyo Europe
Zitieren
APA
De Caterina, R., Fronk, E. M., Nunes, J., Lamparter, M., Kirchhof, P., Zoccali, C., & ETNA‐AF Europe Investigators (2026). Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70268
Vancouver
De Caterina R, Fronk EM, Nunes J, Lamparter M, Kirchhof P, Zoccali C, et al. Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70268
BibTeX
@article{DeCaterina2026,
author = {De Caterina, Raffaele and Fronk, Eva-Maria and Nunes, Joana and Lamparter, Mathias and Kirchhof, Paulus and Zoccali, Carmine and ETNA‐AF Europe Investigators, ETNA‐AF Europe Investigators},
title = {Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study},
journal = {European Journal of Clinical Investigation},
year = {2026},
doi = {10.1111/eci.70268}
}
EUVIMED